• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Viralym-M, a T cell product, treats up to 5 different viral infections

Ema

Senior Member
Messages
4,729
Location
Midwest USA
HOUSTON, Aug. 22, 2017 /PRNewswire/ -- ViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, today announced publication of positive data from a Phase 2 clinical trial evaluating its most advanced T-cell immunotherapy product, Viralym-M. The results were reported by ViraCyte lead investigators at Baylor College of Medicine in the Journal of Clinical Oncology1.

Viralym-M is an "off-the-shelf", 3rd party T-cell product that can simultaneously treat up to five viral infections in patents with severely depressed immune systems. In this report, Dr. Ifigeneia Tzannou and colleagues describe administration of Viralym-M in 38 stem cell transplant patients with 45 different viral infections. All patients had either failed, not responded to, or were unable to tolerate standard antiviral therapy.

Viralym-M achieved a 92% overall clinical response after a single infusion and demonstrated efficacy against all five targeted viruses with the following cumulative response rates in infections refractory to standard therapy: 100% for BK virus (n=16), 94% for cytomegalovirus (n=17), 71% for adenovirus (n=7), 100% for Epstein-Barr virus (n=2) and 67% for human herpesvirus-6 (n=3). Thirty-one patients were treated for a single viral infection and seven patients were treated for multiple simultaneous infections. Notably, rapid disease alleviation was reported in patients with BK-associated hemorrhagic cystitis (BK-HC), which can cause incapacitating pain, significant blood loss, and potentially renal failure. There are no current FDA-approved therapies for BK-HC. Viralym-M infusions were safe with only two cases of new onset grade 1 graft-versus-host disease observed, both of which resolved with standard treatment.

Dr. Ann Leen, Chief Scientist at ViraCyte remarked, "The compelling results from this study demonstrate the high safety profile and broad-spectrum efficacy of Viralym-M in these patients and will strongly position our discussions with the FDA as we progress towards a pivotal clinical trial for potential licensure of Viralym-M."

About ViraCyte, LLC

ViraCyte's products restore natural immunity against life threatening viruses in patients with severely weakened immune systems, such as adults and children who have undergone a hematopoietic stem cell transplant (HSCT). ViraCyte's lead T cell products are in Phase 2 and Phase 1 clinical trials, with effectiveness rates of greater than 94% in patients who have failed conventional therapy. More information can be found at www.viracyte.com

ViraCyte is a resident company at JLABS @ TMC, Houston, Texas.

1Tzannou I. et al. J Clin Oncol. 2017;JCO2017730655. PMID: 28783452
 

junkcrap50

Senior Member
Messages
1,330
Thought I'd add this quote from their homepage:
ViraCyte restores the immune defenses of immunocompromised patients by supplying millions of virus-killing T cells obtained from donors, purified, and then expanded and educated to kill specific invading viruses.

Theoretically, you could "educate" the T-cells to enteroviruses too.
 

Sidny

Senior Member
Messages
176
Have there been any further developments with this? The latest lastest news on their site is over a year old now. This in theory and apparently in practice seems like a holy grail antiviral therapy.

Wish this technology could go open source and we could all benefit from eradicating these potentially deadly viral infections without all the red tape involved.

Please keep us updated @Hip on what the company says about trials for me/cfs patients and thank you for asking them.